RT Journal Article
T1 Combined Immune Defect in B-Cell Lymphoproliferative Disorders Is Associated with Severe Infection and Cancer Progression
A1 Ochoa Grullón, Juliana Lucía
A1 Guevara Hoyer, Kissy
A1 Pérez López, Cristina
A1 Pérez de Diego, Rebeca
A1 Peña Cortijo, Ascensión
A1 Polo, Marta
A1 Mateo Morales, Marta
A1 Anguita Mandley, Eduardo
A1 Jiménez García, Carlos
A1 Bolaños, Estefanía
A1 Íñigo, Belén
A1 Medina, Fiorella
A1 Rodríguez de la Peña, Antonia
A1 Izquierdo Delgado, Carmen
A1 Fuente Muñoz, Eduardo de la
A1 Mayol, Elsa
A1 Fernandez Arquero, Miguel
A1 González Fernández, Ataúlfo
A1 Benavente Cuesta, Celina
A1 Sánchez Ramón, Silvia María
AB B cell chronic lymphoproliferative diseases (B-CLPD) are associated with secondary antibody deficiency and other innate and adaptive immune defects, whose impact on infectious risk has not been systematically addressed. We performed an immunological analysis of a cohort of 83 B-CLPD patients with recurrent and/or severe infections to ascertain the clinical relevance of the immune deficiency expression. B-cell defects were present in all patients. Patients with combined immune defect had a 3.69-fold higher risk for severe infection (p = 0.001) than those with predominantly antibody defect. Interestingly, by Kaplan–Meier analysis, combined immune defect showed an earlier progression of cancer with a hazard ratio of 3.21, than predominantly antibody defect (p = 0.005). When B-CLPD were classified in low-degree, high-degree, and plasma cell dyscrasias, risk of severe disease and cancer progression significantly diverged in combined immune defect, compared with predominantly antibody defect (p = 0.001). Remarkably, an underlying primary immunodeficiency (PID) was suspected in 12 patients (14%), due to prior history of infections, autoimmune and granulomatous conditions, atypical or variegated course and compatible biological data. This first proposed SID classification might have relevant clinical implications, in terms of predicting severe infections and cancer progression, and might be applied to different B-CLPD entities.
PB MDPI
SN 2227-9059
YR 2022
FD 2022-08-19
LK https://hdl.handle.net/20.500.14352/72231
UL https://hdl.handle.net/20.500.14352/72231
LA eng
NO This research received no external funding. K.G.-H is supported by The European Social Fund (ESF) through a Río Ortega Grant for Health Research Projects by the Carlos III Health Institute (ISCIII) (CM20/00098).
DS Docta Complutense
RD 21 ago 2024